Screener
Halozyme Therapeutics HALO Total Revenue
Total Revenue at other companies
Segments
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Royalties | $307,699 | $205,639 | $548,380 | $373,831 |
| Product sales, net | 129,626 | 81,510 | 260,050 | 159,551 |
| Revenues under collaborative agreements | 43,674 | 38,570 | 49,277 | 57,198 |
| Total revenues | 480,999 | 325,719 | 857,707 | 590,580 |
| Operating expenses | ||||
| Cost of sales | 79,171 | 46,359 | 158,409 | 94,762 |
| Amortization of intangibles | 29,512 | 17,762 | 59,024 | 35,524 |
| Research and development | 27,664 | 17,543 | 53,224 | 32,342 |
Item 1. Financial Statements
FAQ
- What is Halozyme Therapeutics's total revenue?
- Halozyme Therapeutics (HALO) reported total revenue of $481M in Q2 2026.
- How has Halozyme Therapeutics's total revenue changed year-over-year?
- Halozyme Therapeutics's total revenue increased by 47.7% year-over-year, from $325.72M to $481M.
- What is the long-term trend for Halozyme Therapeutics's total revenue?
- Over 4 years (2021 to 2025), Halozyme Therapeutics's total revenue has grown at a 33.2% compound annual growth rate (CAGR), from $443.31M to $1.4B.
- What does total revenue mean?
- The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.
Ask your AI about Halozyme Therapeutics's total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude